Co-Clinical Drug Response Study in Gastric Cancer
7 patients, 5 drugs tested. Organoid models predicted clinical response with 66.79% accuracy in a prospective co-clinical design.
Challenge
Gastric cancer is highly heterogeneous, and predicting which patients will respond to specific chemotherapy regimens remains a major unmet clinical need.
Approach
PDO models were established from 7 gastric cancer patients and tested against 5 standard-of-care drugs in a prospective co-clinical design, where sensitivity results were generated before treatment decisions were finalized.
Results:
Clinical prediction accuracy: 66.79%. The prospective design validated that organoid-based testing can provide actionable information before clinical treatment begins.
Implication
Demonstrates the feasibility of using PDO testing as a real-time clinical decision support tool in gastric cancer management.